Global Acute Respiratory Distress Syndrome Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Acute Respiratory Distress Syndrome Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Acute Respiratory Distress Syndrome market finds that the global Acute Respiratory Distress Syndrome market reached a value of USD 739.51 million in 2022. It’s expected that the market will achieve USD 1027.63 million by 2028, exhibiting a CAGR of 5.64% during the forecast period.

Influence of COVID-19 Outbreak on Acute Respiratory Distress Syndrome Industry Development

20% to 30% of the COVID-19 cases studied by doctors show signs similar to ARDS, and not all COVID-19 pneumonias reflect acute respiratory distress syndrome. Intensive care experts say that unlike acute respiratory distress syndrome, COVID-19 pneumonia usually has obvious characteristics and may require different treatment options. However, the impact of COVID-19 and its spread throughout the world have an impact on the economic operation of the entire world. The research on COVID-19 will produce breakthrough results in a short time. However, as acute respiratory distress syndrome and COVID-19 have similar symptoms, the research of COVID-19 will promote the progress of acute respiratory distress syndrome. For example, the FDA approves Israeli drugs for coronavirus treatment trials.

Researchers hope that Avipadil can treat the so-called acute respiratory distress syndrome (ARDS), which can cause about 50% of COVID-19 deaths.

Drivers

North America and Europe
North America and Europe will continue to account for major market shares. Due to the increased number of ARDS cases in the region, the high diagnosis and treatment rate of ARDS, strong medical infrastructure and good medical awareness, it is expected that the ARDS market share of these two countries will maintain the main market share during the forecast period.
The Asia-Pacific
Countries such as China, India and Japan are driving the growth of the acute respiratory distress syndrome market in the Asia-Pacific region. The country with the highest number of traffic accidents is China. In 2018, China had more than 240,000 traffic accidents. India has the highest traffic fatality rate in the world. India has 1% of the world ’s cars, but it accounts 15% for the world ’s traffic accident deaths. It is expected that population growth in developing countries such as India, China and Japan will increase the demand for cars. More and more vehicles are emitting harmful gases. People inhale these harmful gases and face breathing problems, which can cause acute breathing problems such as asthma, chronic obstructive pulmonary disease (COPD) and ARDS. In turn, this may drive regional market growth in the coming years. Due to the growth of lung and brain injuries caused by traffic accidents in the Asia-Pacific region, the large population, the increasing demand for automobiles, and the continuous development of health care infrastructure will promote the growth of the Asia-Pacific region in the acute respiratory distress syndrome market.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

GE Healthcare is one of the major players operating in the Acute Respiratory Distress Syndrome market, holding a share of 13.55% in 2023.

Faron Pharmaceuticals Ltd. offers drug discovery and development services. The Company focuses on the treatment of acute organ traumas, cancer immunotherapy, and metabolic syndrome vasculopathies.

Techpool Bio-Pharma is a biopharmaceutical company focused on biopharmaceutical R & D, production and marketing.

Segmentation Overview:

Among different product types, Lung Injury segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Acute Respiratory Distress Syndrome market covered in Chapter 3:

Apeiron Biologics
BioMarck Pharmaceuticals
Apeptico Forschung und Entwicklung GmbH
Faron Pharmaceuticals
Athersys
GE Healthcare
United Therapeutics
Hamilton Medical
Cynata Therapeutics
Implicit Bioscience
Techpool Bio-Pharma

In Chapter 4 and Chapter 14.2, on the basis of types, the Acute Respiratory Distress Syndrome market from 2018 to 2029 is primarily split into:

Brain Injury
Lung Injury

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Acute Respiratory Distress Syndrome market from 2018 to 2029 covers:

Hospitals
Clinics
Ambulatory Service Centers
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)